These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33183742)

  • 1. Translating science into guidance on the management of dyslipidaemias.
    De Backer GG
    Atherosclerosis; 2020 Dec; 315():145-147. PubMed ID: 33183742
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future.
    Catapano AL; Ray KK; Tokgözoglu L
    Atherosclerosis; 2022 Jan; 340():51-52. PubMed ID: 34863532
    [No Abstract]   [Full Text] [Related]  

  • 3. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman M; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D; ;
    Atherosclerosis; 2011 Jul; 217(1):3-46. PubMed ID: 21882396
    [No Abstract]   [Full Text] [Related]  

  • 4. The new joint EAS/ESC guidelines for the management of dyslipidaemias.
    Catapano AL; Chapman J; Wiklund O; Taskinen MR
    Atherosclerosis; 2011 Jul; 217(1):1. PubMed ID: 21722901
    [No Abstract]   [Full Text] [Related]  

  • 5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 6. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 7. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Kardiol Pol; 2016; 74(11):1234-1318. PubMed ID: 27910077
    [No Abstract]   [Full Text] [Related]  

  • 8. Similarities and differences between European and United States guidelines for the management of dyslipidaemias.
    Reiner Ž
    Kardiol Pol; 2015; 73(7):471-7. PubMed ID: 26189467
    [No Abstract]   [Full Text] [Related]  

  • 9. Dyslipidaemias: new mechanistic insights and the 2016 ESC Guidelines.
    Lüscher TF
    Eur Heart J; 2016 Oct; 37(39):2963-2965. PubMed ID: 27923852
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.
    Sisson EM; Pamulapati L; Bucheit JD; Kelly MS; Dixon DL
    Pharmacotherapy; 2018 Feb; 38(2):164-171. PubMed ID: 29266309
    [No Abstract]   [Full Text] [Related]  

  • 11. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 12. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?
    Dykun I; Mahabadi AA; Rassaf T
    Eur Heart J; 2020 Jun; 41(24):2331. PubMed ID: 32031601
    [No Abstract]   [Full Text] [Related]  

  • 13. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 14. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 15. Northern light: a commentary on the 2009 Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in adults.
    Schaefer EJ
    Clin Chem; 2010 Apr; 56(4):502-4. PubMed ID: 20185622
    [No Abstract]   [Full Text] [Related]  

  • 16. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 17. Dyslipidaemia and the military patient.
    Carter NJ; Hill NE; Nicol ED; Hollis S; Patil Mead ML; Thompson GR
    J R Army Med Corps; 2015 Sep; 161(3):206-10. PubMed ID: 26246352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin efficacy in primary CVD prevention might diminish with patient age.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2019 Apr; 16(4):200. PubMed ID: 30783252
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing dyslipidaemia for the primary prevention of cardiovascular disease.
    Ryan A; Heath S; Cook P
    BMJ; 2018 Mar; 360():k946. PubMed ID: 29572251
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of dyslipidaemias: The New 2019 ESC/EAS-Guideline].
    Vogt A; Weingärtner O
    Dtsch Med Wochenschr; 2021 Jan; 146(2):75-84. PubMed ID: 33465803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.